Presented at the RSNA 2022.
Learning Objectives:
=To know that benefits arise from true results (TP/TN) and harm from false results (FP/FN)
=The harm from the highly variable false-positive rate of MRI dominates false-negative harm
=It is necessary to prioritize urologic/patients’ preferences by the tolerance to potential harm
=Strategies that maintain benefits while reducing the harms include
(1) changing the MRI threshold for biopsy according to disease prevalence,
(2) basing biopsy decisions using the PI-RADS suspicion category and the PSA density,
(3) optimizing the biopsy strategy adopted after MRI, and
(4) adapting the histopathologic assessments by the biopsy strategy used